US 11,806,373 B2
Therapeutic pharmaceutical compositions
Nikole Kimes, San Francisco, CA (US); Ricardo Valladares, Brookhaven, GA (US); and Neeraja Vajrala, Burlingame, CA (US)
Assigned to SIOLTA THERAPEUTICS, INC., San Carlos, CA (US)
Filed by Siolta Therapeutics, Inc., San Carlos, CA (US)
Filed on May 25, 2022, as Appl. No. 17/824,495.
Application 17/824,495 is a continuation of application No. 17/475,228, filed on Sep. 14, 2021, granted, now 11,406,675.
Application 17/475,228 is a continuation of application No. PCT/US2020/054444, filed on Oct. 6, 2020.
Claims priority of provisional application 62/911,873, filed on Oct. 7, 2019.
Prior Publication US 2022/0362313 A1, Nov. 17, 2022
Int. Cl. A01N 63/00 (2020.01); A61K 35/747 (2015.01); A61K 35/741 (2015.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 35/741 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01)] 20 Claims
 
1. A method for a growth of Akkermansia sp. comprising performing a plurality of inoculation rounds with an increasing amount of growth media,
wherein an inoculation round of the plurality of inoculation rounds comprises use of at least about 5% by volume of a total batch material of a preceding inoculation round of the inoculation round of the plurality of inoculation rounds, and
wherein a growth media of at least one inoculation round of the plurality of inoculation rounds is at least about 20 liters (L).